[eDisclosure Notice] Kim Dong-gwan Vice Chairman, Hanwha Aerospace 'Grip' (Morning Summary)

Kim Dong-kwan, Vice Chairman of Hanwha Group

[Asia Economy Reporter Junho Hwang] Kim Dong-gwan, the eldest son of Kim Seung-yeon, chairman of Hanwha Group and regarded as the next-generation leader to lead the group, was newly appointed as co-CEO of Hanwha Aerospace on the 1st. He is analyzed to be expanding his management footprint in earnest after being appointed vice chairman (CEO) of Hanwha Solutions on the 29th of last month. Kim is an inside director of Hanwha, CEO of Hanwha Solutions, and also serves as a non-executive director of Setrec Eye.

The following are disclosures from Hanwha Aerospace and other announcements made during the morning of the same day.

▲ Hanwha Aerospace (012450) announced on the 1st that it has newly appointed Kim Dong-gwan as CEO and changed to a dual CEO system with Shin Hyun-woo and Kim Dong-gwan.

▲ LG Chem = Applied for a clinical trial plan for the Phase 3 US clinical trial of the gout treatment drug ‘Tigulixostat’ (LC350189) (research project name ‘EURELIA 2 Study’). The clinical trial will involve approximately 2,600 global participants with a treatment period of 12 months. The clinical trial design includes randomized allocation, double-blind, active drug and placebo control, etc.

▲ Humasis = Decided to cancel treasury shares worth 5.06 billion KRW. The shares to be canceled are 313,480 common shares, and the scheduled cancellation date is the 19th of this month.

▲ Finetech = Signed a supply contract for secondary battery manufacturing equipment with Sangshin EDP. The contract amount is 8.2 billion KRW, which corresponds to 12.31% of the 2021 sales. The contract period is from the 2nd of this month to March 30, 2023.

▲ Kolon Global = Won an order for the construction of 3BL of Asan Hujae District multi-family housing from Sambo Industry worth 276.4 billion KRW. This corresponds to 5.82% of Kolon Global’s recent sales.

▲ KG Steel = Cactus Special Situation No.1 Co., Ltd. sold 6 million common shares through off-hours trading. The disposal price was 11,300 KRW per share, reducing Cactus Special Situation No.1 Co., Ltd.’s KG Steel holdings from 32 million shares to 26 million shares.

▲ Eutilex = Applied to the Ministry of Food and Drug Safety for an IND (Investigational New Drug) application for the Phase 1 clinical trial of ‘EU307’ (GPC3-IL18 CAR-T therapy) targeting patients with GPC3-positive advanced hepatocellular carcinoma who failed standard therapy. The clinical trial institutions are five university hospitals in Korea.